EMA Recommends Mavorixafor Approval, X4 Pharma Secures Cash Runway Through 2028
Summary
X4 Pharmaceuticals reported its fourth quarter and full year 2025 financial results, alongside significant corporate updates. The European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for mavorixafor in WHIM syndrome, a critical step towards potential EU approval. Crucially, the company announced a cash runway through 2028, directly addressing and mitigating the "going concern" disclosure from its 10-K filing earlier today. This financial clarity, combined with a major regulatory milestone and progress in its 4WARD Phase 3 trial, provides substantial positive news for the company despite the reported net loss for the year. Traders will be watching for the European Commission's final approval decision in Q2 2026 and continued enrollment progress for the 4WARD trial.
At the time of this announcement, XFOR was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $311.3M. The 52-week trading range was $1.35 to $10.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.